Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2025;31(Suppl):S228-S254. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0824

View: 4763 Download: 672 Web of Science: 4 Crossref: 8

Hepatitis E as a trigger for acute-on-chronic liver failure

Maria Buti, Juan Carlos Ruiz-Cobo, Rafael Esteban, Mar Riveiro-Barciela

Clin Mol Hepatol. 2025;31(Suppl):S196-S204. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0758

View: 1551 Download: 138 Web of Science: 1 Crossref: 2

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 1899 Download: 161 Web of Science: 1 Crossref: 1

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2025;31(Suppl):S51-S75. Published online June 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246

View: 6239 Download: 231 Web of Science: 3 Crossref: 3

Reply to Correspondence

Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”

Georg Semmler, Lorenz Balcar, Mattias Mandorfer

Clin Mol Hepatol. 2025;31(2):e224-e225. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0149

View: 578 Download: 31

Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):e218-e220. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0070

View: 616 Download: 24

Correspondence

TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure? Correspondence to editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”

Anja Tiede, Benjamin Maasoumy

Clin Mol Hepatol. 2025;31(2):e176-e179. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0135

View: 533 Download: 18 Crossref: 1

Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(2):e173-e175. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2025.0001

View: 713 Download: 28 Crossref: 1

Editorial

Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”

Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng

Clin Mol Hepatol. 2025;31(2):620-624. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1131

View: 1425 Download: 60 Crossref: 2

A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):610-614. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1099

View: 843 Download: 41 Crossref: 2

From invasive to intuitive: The emerging role of non-invasive models in hepatic decompensation: Editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”

Akhil Deshmukh, Rakhi Maiwall

Clin Mol Hepatol. 2025;31(2):577-580. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0661

View: 2090 Download: 34 Crossref: 1

Original Article

Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):525-547. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0835

View: 3533 Download: 279 Crossref: 5

Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters

Lung-Yi Mak, Mark Anderson, Michael Stec, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, Rex Wan-Hin Hui, Wai-Kay Seto, Gavin Cloherty, Man-Fung Yuen

Clin Mol Hepatol. 2025;31(2):460-473. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0724

View: 1176 Download: 103

Editorial

Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers: Editorial on “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(1):301-303. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0716

View: 1122 Download: 75 Crossref: 1

Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Won Sohn

Clin Mol Hepatol. 2025;31(1):277-280. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0823

View: 1339 Download: 42 Crossref: 1

Original Article

Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis

Anja Tiede, Lena Stockhoff, Zhaoli Liu, Hannah Rieland, Jim B. Mauz, Valerie Ohlendorf, Birgit Bremer, Jennifer Witt, Anke Kraft, Markus Cornberg, Jan B. Hinrichs, Bernhard C. Meyer, Heiner Wedemeyer, Cheng-Jian Xu, Christine S. Falk, Benjamin Maasoumy

Clin Mol Hepatol. 2025;31(1):240-255. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0587

View: 1950 Download: 234 Web of Science: 1 Crossref: 2

Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis

Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(1):227-239. Published online November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0564

View: 1802 Download: 142 Crossref: 6

Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)

Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Federico Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi

Clin Mol Hepatol. 2025;31(1):105-118. Published online July 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0198

View: 3431 Download: 320 Web of Science: 2 Crossref: 2

Review

Roles of X-box binding protein 1 in liver pathogenesis

Jihoon Tak, Yun Seok Kim, Sang Geon Kim

Clin Mol Hepatol. 2025;31(1):1-31. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0441

View: 2554 Download: 176

Snapshot

Examining the therapeutic landscape of beta-blockers in portal hypertension

Anna Brujats, Càndid Villanueva

Clin Mol Hepatol. 2024;30(4):1055-1059. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0144

View: 6701 Download: 80 Crossref: 1

Original Article

Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Ki Tae Suk

Clin Mol Hepatol. 2024;30(4):845-862. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0349

View: 5474 Download: 992 Web of Science: 6 Crossref: 6

Editorial

Modified quick-SOFA score: Can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?: Editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”

Simone Incicco, Salvatore Piano

Clin Mol Hepatol. 2024;30(4):695-697. Published online June 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0409

View: 1752 Download: 33 Web of Science: 1 Crossref: 1

Original Article

Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):235-246. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0485

View: 7871 Download: 319 Web of Science: 24 Crossref: 30

Letter to the Editor

Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Hinpetch Daungsupawong, Viroj Wiwanitkit

Clin Mol Hepatol. 2024;30(1):111-112. Published online October 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0394

View: 2813 Download: 72

Correspondence

Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”

Ji Young Ryu, Seon Ha Baek, Sejoong Kim

Clin Mol Hepatol. 2023;29(4):1048-1049. Published online August 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0261 Correction in: Clin Mol Hepatol 2024;30(1):134

View: 2780 Download: 47

Original Article

Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection

Jeongin Yoo, Heejin Cho, Dong Ho Lee, Eun Ju Cho, Ijin Joo, Sun Kyung Jeon

Clin Mol Hepatol. 2023;29(4):1029-1042. Published online August 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0190

View: 4423 Download: 169 Web of Science: 6 Crossref: 5

Review

Evidence-based hyponatremia management in liver disease

Ji Young Ryu, Seon Ha Baek, Sejoong Kim

Clin Mol Hepatol. 2023;29(4):924-944. Published online June 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0090

View: 5562 Download: 309 Web of Science: 7 Crossref: 7

Hepatorenal syndrome: Current concepts and future perspectives

Chan-Young Jung, Jai Won Chang

Clin Mol Hepatol. 2023;29(4):891-908. Published online April 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0024

View: 10082 Download: 1,362 Web of Science: 9 Crossref: 10

Correspondence

Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng

Clin Mol Hepatol. 2023;29(3):821-822. Published online May 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0183

View: 3625 Download: 77 Web of Science: 2 Crossref: 2

Letter to the Editor

Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Hassam Ali

Clin Mol Hepatol. 2023;29(3):813-814. Published online May 19, 2023

DOI: https://doi.org/10.3350/cmh.2023.0120

View: 3156 Download: 76 Web of Science: 1 Crossref: 1

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |

Viewed By 10476	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7409	MAFLD: How is it different from NAFLD?
Viewed By 5352	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4781	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4763	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 338	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Search